This led to the establishment of CEA-targeted CAR-T cells in phase I clinical trials to evaluate the efficacy, safety, and maximum tolerated dose of this therapy in various solid tumors including lung cancer (NCT02349724, NCT04348643). Here, CEACAM5 is linked to lung carcinoma.